DJIA 17,683.58 -46.53 -0.26%
NASDAQ 4,991.94 -17.27 -0.34%
S&P 500 2,068.76 -8.02 -0.39%
market minute promo

Ophthotec (NASDAQ: OPHT)

52.39 0.56 (1.08%)

Quote as of

company name or ticker

Recent Quotes

OPHT $52.39 1.08%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $51.20
Previous Close $51.83
Daily Range $51.07 - $52.40
52-Week Range $35.38 - $58.29
Market Cap $1.8B
P/E Ratio -24.80
Dividend (Yield) $0.00 (0.0%)
Volume 241,078
Average Daily Volume 288,835
Current FY EPS -$2.83



Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website:

News & Commentary

Pop! 3 To Buy If Biotech Stocks Burst

Biotech stocks are falling slightly from their lofty levels, and that may create some interesting opportunities to buy.

Commit To Buy Ophthotech Corp At $40, Earn 8.1% Annualized Using Options

Ophthotech's (OPHT) CEO David Guyer on Q1 2015 Results - Earnings Call Transcript

Will AVEO Pharmaceuticals (AVEO) Surprise This Earnings? - Analyst Blog

AVEO Upgraded to Strong Buy, Add to Your Portfolio - Analyst Blog

3 Little-Known Biotechs Working On Potential Blockbusters

These three biotechs have promising drugs in their pipelines that address billion dollar drug markets.

3 Little-Known Stocks I'm Glad I Bought

Ophthotech Corp, Portola Pharmaceuticals Inc., and Insys Therapeutics Inc., have been top performers this past year.

2 Tiny Biotechs That Could Have Blockbuster Opportunity

Got risk tolerance? Check out these two small cap biotechs with huge potential.

Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog

Ophthotech's (OPHT) CEO Dr. David Guyer on Q4 2014 Results - Earnings Call Transcript

See More OPHT News...